Suzhou Ruiming New Drug Research and Development

Suzhou Ruiming New Drug Research and Development is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. Founded in 2017 by Dr. Ming-Qiang Zhang, a veteran of the global pharmaceutical industry with leadership experience at Amgen and GSK, the company focuses on high-unmet-need areas including oncology, immunology, and metabolic disorders. Its pipeline features proprietary candidates such as RM-001 and RM-101, which are currently undergoing clinical evaluation for cancer and autoimmune conditions. Ruiming leverages a robust medicinal chemistry platform to optimize drug-like properties and clinical efficacy. The company is supported by prominent venture capital firms and operates within the Suzhou Industrial Park biotech ecosystem.